Betamethasone disodium phosphate/chloramphenicol/colistimethate sodium/tetracycline

Drug Profile

Betamethasone disodium phosphate/chloramphenicol/colistimethate sodium/tetracycline

Latest Information Update: 29 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SIFI
  • Class Anti-inflammatories; Antibacterials; Chloramphenicols; Eye disorder therapies; Polymixins; Pregnadienetriols; Tetracyclines
  • Mechanism of Action Cell membrane structure inhibitors; Glucocorticoid receptor agonists; Peptidyltransferase inhibitors; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Eye disorders

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top